Anna Buscall is a corporate transactions and advisory specialist. Ms. Buscall has advised on a wide range of transactions, including public and private M&A (both domestic and cross border), joint ventures in various industries and equity issues, as well as demergers, restructurings and corporate advisory work. She has a particularly strong track record in advising on transactions in the life sciences sector.

Prior to joining the firm in 2012, Ms. Buscall practiced with a Magic Circle firm in London.

Experience

  • SpePharm AG, an affiliate of independent European specialty pharmaceutical company Norgine B.V., on its sale of SAVENE® - a drug used for the treatment of extravasation in anthracycline chemotherapy in adults - to LSE and AIM-listed global pharmaceutical company Clinigen Group plc.
  • Recordati, a pharmaceutical company based in Milan, Italy, in its acquisition of 90% of Opalia Pharma S.A., a Tunisian pharmaceutical company with headquarters in Ariana, a suburb of Tunis for TND 80 million (approx. € 37 million).
  • Recordati in its €93m acquisition of Madrid-based pharmaceutical company Laboratorios Casen Fleet S.L.U. 
  • Pfizer on its innovative agreement (joint venture and business combination) with GSK to combine their HIV portfolios, creating a new world-leading company focused solely on research, development and commercialisation of HIV medicines. The combined portfolio had sales of more than GBP 1.6bn.
  • GE Healthcare on its agreement to acquire PAA Laboratories GmbH, headquartered in Linz Austria, and with operations in Germany, the US, the UK, France, Australia and Canada.

  • Takeda Pharmaceutical Company on its acquisition of Paradigm Therapeutics Ltd from VC investors and management.
  • Celltech Group plc (UK listed biotech), having advised on its original IPO in 1993, on a number of matters including: on the sale of its vaccines business to PowederJect Pharmaceuticals; on its takeover (recommended general offer) by UCB SA, offer value GBP1.5bn.

Perspectives

Life Sciences (UK) 2019 (pdf)
Chambers Global Practice Guide
Life Sciences (UK) 2018 (pdf)
Chambers Global Practice Guide
Competition Law in Life Sciences
Arnold & Porter Kaye Scholer, London
UK Companies and LLPs: Duty to Report on Payment Practices and Performance
Advisory
Are you ready with your Persons with Significant Control Register? – Implementation Update 2016
Arnold & Porter Advisory
More

Recognition

The Legal 500 UK
Corporate and Commercial: M&A Mid-Market (2012, 2015-2019)
Venture Capital (2012, 2014)
Who's Who Legal UK
Life Sciences: Transactional (2016)
PLC Which lawyer?
Life Sciences: Corporate (2012)
More

Credentials

Education
  • LLM, Queens' College Cambridge
  • LLB (Hons), University College London
Admissions
  • England and Wales
Overview

Email Disclaimer